Decoy Therapeutics Enhances Communication with Investors via Webull Corporate Connect Service

Decoy Therapeutics Joins Webull Corporate Connect Service

Decoy Therapeutics, Inc., a pioneering biopharmaceutical company focused on developing advanced peptide conjugate therapeutics, has made a significant step in enhancing its communication with stakeholders. As of February 11, 2026, Decoy has officially joined the Webull Corporate Connect Service (CCS) platform. This move aims to foster improved transparency and engagement with its growing base of shareholders and potential investors.

The overarching goal of Decoy's participation in the Webull platform is to provide an effective channel for disseminating crucial corporate information. Through this portal, shareholders will have access to real-time updates concerning various corporate communications, including news announcements, earnings reports, product developments, presentations, and much more. This initiative reflects Decoy's commitment to ensuring that investors are kept informed about the company's strategic initiatives and advancements.

Rick Pierce, the CEO of Decoy Therapeutics, emphasized the importance of open communication in his statement. He remarked, "At Decoy Therapeutics, we are committed to clear and transparent communication with our shareholders. As we advance our programs and strategic initiatives, expanding awareness and engagement with the investor community is a critical part of our approach. Joining Webull Corporate Connect complements our existing investor relations efforts and social channels, providing an additional platform to share timely company updates and connect directly with our investors.”

In addition, current users of Webull can easily follow Decoy Therapeutics (NASDAQ: DCOY) via the Webull app on their smartphones or tablets, ensuring they remain updated on the company's latest developments. For those new to Webull, registration for a free account allows any interested individual to access pertinent information about Decoy Therapeutics and its offerings.

About Webull Financial

Webull Corporation operates Webull, a cutting-edge digital investment platform providing services across 14 different markets worldwide, including North America, Asia Pacific, Europe, and Latin America. With over 24 million registered users globally, Webull offers an array of investment services that allow retail investors to access financial markets 24/7. Through the Webull platform, users can trade not only stocks, ETFs, options, and futures but also fractional shares and digital assets, all while having access to market data, community features, and educational resources.

About Decoy Therapeutics

Decoy Therapeutics is at the forefront of biopharmaceutical innovation, leveraging machine learning and artificial intelligence to create high-speed synthesis techniques. This enables Decoy to design and manufacture peptide conjugate drug candidates that specifically target pressing medical needs. Initially, the company is directing its efforts towards addressing respiratory viruses and gastrointestinal cancers. Through strategic financing efforts, including support from institutional investors and non-dilutive capital from prestige funds and programs like the Massachusetts Life Sciences Seed Fund, Google AI startup program, and NVIDIA Inception program, Decoy has positioned itself as a formidable player in the biotech sector.

The company has recently secured funding through awards like the QuickFire Challenge from the Biomedical Advanced Research and Development Authority (BARDA), showcasing its capability to fulfill critical biomedical needs.

Conclusion

By joining the Webull Corporate Connect Service, Decoy Therapeutics not only enhances its communication strategy but also reinforces its dedication to fostering an informed investor base. As the company advances its innovative pipeline and engages with the investor community, it demonstrates a commitment to transparency and proactive communication. Investors looking to stay abreast of Decoy's progress can easily access the company’s updates through the Webull platform, further cementing a robust relationship between Decoy and its stakeholders. This strategic move is set to play a crucial role in Decoy Therapeutics’ journey as it navigates its path in the biopharmaceutical landscape.